Drug Trial Radar · NCT00314951
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
Last checked: Nov 19, 2026Latest source record: Apr 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
629
Actual
Start
May 2, 2006
Primary completion
Jul 23, 2008
Study completion Aug 21, 2008
Sponsor
- Lead sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Apr 17, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
Conditions
- Clostridium Infections
- Diarrhea
Interventions
FidaxomicinDrug
200 mg oral capsules two times daily (q12h regimen)
VancomycinDrug
125 mg capsules q6hr (4 times a day)
Matching Placebo to FidaxomicinDrug
Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cure Rate at End of TherapyTime frame: Study day 10 (+/- 2 days)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.